Css LLC 89bio, Inc. Transaction History

Css LLC

$928 Million
Q3 2025

A detailed history of Css LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Css LLC holds 409,571 shares of ETNB stock, worth $6.08 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares

409,571

Holding current value

$6.08 Million

% of portfolio

0.65%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$8.02 - $14.96 $3.28 Million - $6.13 Million	409,571 New	409,571 $6.01 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $7,293 - $16,905	2,415 Added 2.21%	111,693 $647,000
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $89,683 - $172,502	42,911 Added 64.66%	109,278 $352,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $125,310 - $544,466	36,322 Added 120.89%	66,367 $250,000
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $23,415 - $41,286	2,100 Added 7.51%	30,045 $393,000
Q3 2021 Nov 15, 2021	BUY	$14.91 - $21.31 $74,550 - $106,550	5,000 Added 21.79%	27,945 $547,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $70,638 - $113,540	-4,055 Reduced 15.02%	22,945 $429,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $69,480 - $84,240	-3,000 Reduced 10.0%	27,000 $658,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $730,200 - $1.16 Million	30,000 New	30,000 $770,000

Others Institutions Holding ETNB

# of Institutions

234

Shares Held

156M

Call Options Held

710K

Put Options Held

6.17M

Ra Capital Management, L.P. Boston, MA

19.9M
Shares

$295 Million
5.01% of portfolio
Pentwater Capital Management LP Naples, FL

11.8M
Shares

$174 Million
1.08% of portfolio
Deep Track Capital, LP Greenwich, CT

9.36M
Shares

$139 Million
4.33% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

9.1M
Shares

$135 Million
0.22% of portfolio
Suvretta Capital Management, LLC New York, NY

8.28M
Shares

$123 Million
3.65% of portfolio

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $690M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.

Account